Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy

Eur J Heart Fail. 2013 Oct;15(10):1102-12. doi: 10.1093/eurjhf/hft098. Epub 2013 Jun 20.

Abstract

Aims: To evaluate the accuracy and cost-effectiveness of different screening strategies to identify systolic and/or diastolic asymptomatic LV dysfunction (ALVD), as well as pre-clinical (stage B) heart failure (HF), in a community of elderly subjects in Italy.

Methods and results: A sample of 1452 subjects aged 65-84 years were chosen from the original cohort of 2001 randomly selected residents of the Lazio Region (Italy), as a part of the PREDICTOR survey. All subjects underwent physical examination, biochemistry/NT-proBNP assessment, 12-lead ECG, and Doppler transthoracic echocardiography (TE). Five strategies were evaluated including ECG, NT-proBNP, TE, and their combinations. Subjects older than 75 years, and with at least two additional risk factors, were defined as being high-risk for HF (435), whereas the remaining 1017 were defined at low risk. Screening characteristics and cost-effectiveness (cost per case) of the five strategies to predict systolic (EF <50% ) or diastolic ALVD and pre-clinical HF (stage B) were compared. NT-proBNP was the most accurate and cost-effective screening strategy to identify systolic and moderate to severe diastolic LV dysfunction without a difference between the high-risk and low-risk groups. Adding ECG to the NT-proBNP assessment did not improve the detection of pre-clinical LV dysfunction. TE-based screening was the least cost-effective strategy. In fact, all screening strategies were inadequate to identify stage B HF.

Conclusions: In a community of elderly people, NT-proBNP is the most accurate and cost- effective pre-screening strategy to identify systolic and moderate to severe diastolic LV dysfunction.

Keywords: Asymptomatic left ventricular dysfunction; Elderly; Heart failure screening; Heart failure stage B; Prevention.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Asymptomatic Diseases
  • Cost-Benefit Analysis
  • Diastole
  • Echocardiography, Doppler / economics
  • Echocardiography, Doppler / methods
  • Electrocardiography / economics
  • Electrocardiography / methods
  • Female
  • Heart Failure / blood
  • Heart Failure / diagnosis*
  • Heart Failure / diagnostic imaging
  • Humans
  • Italy
  • Male
  • Mass Screening / economics
  • Mass Screening / methods
  • Natriuretic Peptide, Brain / blood
  • Peptide Fragments / blood
  • Predictive Value of Tests
  • Risk Factors
  • Sensitivity and Specificity
  • Stroke Volume
  • Systole
  • Ventricular Dysfunction, Left / blood
  • Ventricular Dysfunction, Left / diagnosis*
  • Ventricular Dysfunction, Left / diagnostic imaging

Substances

  • Peptide Fragments
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain